The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Oprah Winfrey says taking weight-loss medications like Ozempic and Wegovy challenged and helped her understand the truth ...

On the latest episode of her podcast, Oprah Winfrey opened up about how her opinion of “thin people” changed after she was able to lose weight herself with the help of weight loss medications.

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...